Login / Signup

Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.

Chihiro YonedaJunji KobayashiNobuichi Kuribayashi
Published in: Diabetology international (2024)
Switching from a DPP-4i to oral semaglutide may be useful for Japanese patients with T2D who have inadequate glycemic or BW control. However, its utility may be limited by gastrointestinal adverse effects in certain patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • type diabetes
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes
  • metabolic syndrome
  • insulin resistance